Research and Markets: Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/cbrsvk/competitor) has announced the addition of the "Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors" report to their offering.

The present Competitive Intelligence Report about EGF-R Antibodies -Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of December 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted sales of more than US$ 2.3 bln in the year 2011. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies.

The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies.

Competitor projects are listed in a tabular format providing information on:

- Drug Codes,

- Target / Mechanism of Action,

- Class of Compound,

- Company,

- Product Category,

- Indication,

- R&D Stage and

- additional comments with a hyperlink leading to the source of information.

Companies Mentioned

- Abbott

- Amgen

- Avesthagen

- Biocon

- BioXpress

- Bristol-Myers Squibb

- Celltrion

- Daiichi Sankyo

- Eli Lilly

- Glycotope

- Harvest Moon Pharmaceuticals

- Hospira

- Innogene Kalbiotech

- ISU Abxis

- Kyowa Hakko Kirin

- Merck KGaA (Merck Serono)

- Merrimack Pharmaceuticals

- Oncoscience

- PanGenerika

- PanPharmaceuticals USA

- Pfizer

- PlantForm

- Roche (Genentech)

- Shanghai BioMabs Pharmaceutical Co

- Symphogen

- Takeda Pharmaceutical Co

- YM Biosciences (CIMYM Biosciences)

For more information visit http://www.researchandmarkets.com/research/cbrsvk/competitor.